24
FEATURE:
A
DEPARTMENTS
TEVA
6
8
10
An instructive view of Israel's global powerhouse in
traditional pharma, generics, and "special generics" at a
critical time for the company and its leader, Dr. Jeremy
Levin, president and CEO
14
16
20
48
50
October 2013
CONTENTS
Welcome to
Life Science Leader
54
56
60
30
38
42
62
GSK'S CASE FOR
DATA TRANSPARENCY
THE ART OF
THE TURNAROUND
PHARMA
BRAND PROTECTION
66
A chairman of the board gives tips
on how to assess and fix a troubled
pharma company.
Why it's important to formalize the
brand protection function
Perry Nisen, senior VP of science and
innovation at GSK, discusses sharing of
clinical-trials data.
BRAND
Editor's Note
Editorial Board/Ask The Board
Capitol Perspectives
Low-Income Beneficiaries' Drugs
Companies To Watch
Inovio
Outsourcing Insights
API Manufacturing
Bio Innovation Notes
Innovation In Chromatography
Contract Sourcing
Trials & Innovations
R&D; And Clinical Trials
Risk-Based Monitoring
R&D; And Clinical Trials
Adaptive Clinical Design
Global Update
The Brazil Pharma Market
Industry Leader
Big Data
Industry Leader
Partner With Academia
Leadership Lessons
Building A Diverse Team
@RFWrightLSL
linkedin.com/in/robertfwright
pinterest.com/rfwrightlsl
facebook.com/LifeScienceLeader
4
LifeScienceLeader.com
October 2013